NASDAQ:AKCA - Akcea Therapeutics Stock Price, Forecast & News

Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AKCA stock has decreased by 1.0% and is now trading at $13.31. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akcea Therapeutics.

Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Akcea Therapeutics.

Akcea Therapeutics Inc (NASDAQ:AKCA) posted its earnings results on Tuesday, February, 25th. The company reported $0.86 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $2.10 by $1.24. The business had revenue of $277.48 million for the quarter, compared to analysts' expectations of $225.94 million. Akcea Therapeutics had a net margin of 8.35% and a return on equity of 10.03%. The firm's revenue for the quarter was up 2620.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.79) earnings per share. View Akcea Therapeutics' earnings history.

4 equities research analysts have issued 1 year target prices for Akcea Therapeutics' shares. Their forecasts range from $24.00 to $41.00. On average, they anticipate Akcea Therapeutics' share price to reach $34.67 in the next year. This suggests a possible upside of 160.5% from the stock's current price. View analysts' price targets for Akcea Therapeutics.

News coverage about AKCA stock has been trending negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akcea Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAkcea Therapeutics.

Akcea Therapeutics saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 3,366,000 shares, a decline of 7.0% from the February 27th total of 3,620,000 shares. Based on an average daily trading volume, of 254,300 shares, the short-interest ratio is currently 13.2 days. Approximately 36.4% of the shares of the stock are short sold. View Akcea Therapeutics' Current Options Chain.

Some companies that are related to Akcea Therapeutics include Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), Horizon Therapeutics (HZNP), Reata Pharmaceuticals (RETA), Amarin (AMRN), Forty Seven (FTSV), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR) and Nektar Therapeutics (NKTR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH).

(AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Akcea Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (11.50%), State Street Corp (0.71%), Point72 Asset Management L.P. (0.27%), Geode Capital Management LLC (0.27%), Charles Schwab Investment Management Inc. (0.16%) and Russell Investments Group Ltd. (0.12%). Company insiders that own Akcea Therapeutics stock include Damien Mcdevitt, Ionis Pharmaceuticals Inc, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos and Sarah Boyce. View institutional ownership trends for Akcea Therapeutics.

AKCA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Rafferty Asset Management LLC, Geode Capital Management LLC, ProShare Advisors LLC, Nuveen Asset Management LLC, and Motley Fool Asset Management LLC. Company insiders that have sold Akcea Therapeutics company stock in the last year include Damien Mcdevitt, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos, and Sarah Boyce. View insider buying and selling activity for Akcea Therapeutics.

AKCA stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, Russell Investments Group Ltd., State Street Corp, Charles Schwab Investment Management Inc., Amia Capital LLP, Virtus ETF Advisers LLC, and California Public Employees Retirement System. View insider buying and selling activity for Akcea Therapeutics.

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AKCA stock can currently be purchased for approximately $13.31.

Akcea Therapeutics has a market capitalization of $1.35 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe. View additional information about Akcea Therapeutics.

The official website for Akcea Therapeutics is http://www.akceatx.com/.

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]